Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Non-Current Debt: 2015-2024

Historic Non-Current Debt for China Pharma Holdings (CPHI) over the last 8 years, with Dec 2024 value amounting to $1.4 million.

  • China Pharma Holdings' Non-Current Debt fell 5.93% to $1.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.3 million, marking a year-over-year decrease of 5.93%. This contributed to the annual value of $1.4 million for FY2024, which is 1.47% down from last year.
  • As of FY2024, China Pharma Holdings' Non-Current Debt stood at $1.4 million, which was down 1.47% from $1.4 million recorded in FY2023.
  • China Pharma Holdings' 5-year Non-Current Debt high stood at $1.4 million for FY2023, and its period low was $904,228 during FY2020.
  • Its 2-year average for Non-Current Debt is $1.4 million, with a median of $1.4 million in 2023.
  • Data for China Pharma Holdings' Non-Current Debt shows a maximum YoY tumbled of 57.95% (in 2020) over the last 5 years.
  • Over the past 3 years, China Pharma Holdings' Non-Current Debt (Yearly) stood at $904,228 in 2020, then reached $1.4 million in 2023, then declined by 1.47% to $1.4 million in 2024.